RIPK1 and cancer: Many conventional drugs are known to induce DNA methylation or histone deacetylation-dependent loss of RIP3, resulting in chemotherapy-resistant cancer cells such as those used in this study.60 In contrast to chemotherapeutics such as doxorubicin, RaST can overcome this resistance by upregulating the expression of RIP1 and RIP3 to pivot into an alternative necroptosis cell death pathway.